Items Tagged ‘Acute Myeloid Leukemia’

November 17th, 2016

FDA Priority Review Granted for Midostaurin in Leukemia

By

The United States Food and Drug Administration (FDA) has granted priority review to PKC412 (midostaurin) in the treatment of newly diagnosed acute myeloid leukemia (AML) with the FLT3 mutation, as well as for the treatment of advanced systemic mastocytosis (SM). The diagnostic test to detect the FLT3 mutation has also been accepted for review by […]

View full entry

Tags: Acute Myeloid Leukemia, AML, fda, FLT3 mutation, itchy skin, Leukemia, mast cell, mastocytosis, midostaurin, News, PKC412


August 9th, 2016

Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia

By

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational drug Pracinostat in combination with azacitidine for the treatment of elderly patients with newly diagnosed acute myeloid leukemia (AML). Acute myeloid leukemia (AML) is a cancer of the bone marrow (spongy portion found in the middle of bones) and blood […]

View full entry

Tags: Acute Myeloid Leukemia, AML, azacitidine, Breakthrough Therapy Designation, elderly, FDA. BTD, HDACs, Leukemia, News, Pracinostat


December 31st, 2015

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings

By

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH) Annual Meeting, in Orlando, December 5-8, made it increasingly clear that new discoveries […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, all, AML, ASH, blood cancer, CAR T, Chronic Lymphocytic Leukemia, CLL, fda, Leukemia, Lymphoma


December 30th, 2015

Myeloablative Treatment Regimens Superior to Reduced Intensity Treatment for AML and MDS Patients Undergoing Stem Cell Transplant

By

Hematopoietic Stem Cell Transplant (SCT) is a standard and potentially curative treatment for individuals with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically only high dose myeloablative treatment regimens were utilized since they were thought necessary to eradicate the malignant cells in the bone marrow. In recent years, SCT physicians have increasingly used reduced […]

View full entry

Tags: Acute Myeloid Leukemia, Allogeneic Stem Cell Transplant, AML, General Myelodysplastic Syndrome, hematopoietic stem cell transplant, Leukemia, MDS, Myelodysplastic Syndrome, News, sct, Stem Cell Transplant


December 15th, 2015

Midostaurin Improves Survival in Subset of Acute Myeloid Leukemia

By

The targeted agent, midostaurin, has demonstrated a survival improvement among patients with acute myeloid leukemia (AML) that has the TMS-like tyrosine kinase 3 (FLT3) mutation. These results were presented at a plenary session at the 2015 annual meeting of the American Society of Hematology (ASH), in Orlando, Florida. Acute myeloid leukemia is a type of […]

View full entry

Tags: Acute Myeloid Leukemia, FLT3, Leukemia, midostaurin, myeloid leukemia, News, targeted agent


July 30th, 2015

Promising Survival for AML Patients Treated with Stem Cells from Related Half Matched Donor

By

Patients with acute myeloid leukemia (AML) may have a promising new treatment option. Research shows that stem cell transplant from a “half matched” related donor plus chemotherapy results in similar survival as a transplant from an unrelated matched donor. Further more, transplant from a half matched donor lowers the risk of graft-versus-host disease (GVHD). These […]

View full entry

Tags: Acute Myeloid Leukemia, AML, aploidentical transplant, half matched dono, Leukemia, News


January 28th, 2015

CPX-351 Receives Fast Track Designation for Secondary Acute Myeloid Leukemia in Elderly Patients

By

The U. S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigational drug CPX-351, a liposomal formulation of cytarabine-daunorubicin, for the treatment of elderly patients with secondary acute myeloid leukemia. Acute myeloid leukemia (AML) is a cancer of the bone marrow (spongy portion found in the middle of bones) and blood […]

View full entry

Tags: Acute Myeloid Leukemia, AML, cpx-351, cytaribine-dauorubicin, fda, Leukemia, News


December 8th, 2014

Orphan-drug Designation from FDA for Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

By

(OMNI-CancerConnect) Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the US Food and Drug Administration (FDA) has granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60. Actimab-A is currently in […]

View full entry

Tags: actimab-a, Acute Myeloid Leukemia, AML, Leukemia, News


August 8th, 2014

Exposure to Some Inflammatory Bowel Disease Drugs May Increase Leukemia Risk

By

Thiopurines are an established treatment for inflammatory bowel disease (IBD) patients.  They are used to reduce inflammation and provide symptom relief.  Thiopurine immunosuppressive drugs have now been reported to increase the risk of acute myelod leukemia and myelodysplastic syndrome, a rare bone marrow disorder, seven-fold among IBD patients. These data were recently reported in a […]

View full entry

Tags: Acute Myeloid Leukemia, AML, cancer prevention, General Myelodysplastic Syndrome, Health and Wellness, Leukemia, MDS, Myelodysplastic Syndrome, News, Screening/Prevention Leukemia, thiopurines


December 20th, 2013

Mylotarg Reduces Risk of Relapse in Childhood AML

By

Mylotarg® (gemtuzumab ozogamicin)—a drug that was withdrawn from the market in 2010 because of uncertain benefit and safety concerns—reduces the risk of relapse in children and young adults with acute myeloid leukemia (AML). These results were presented at the 2013 Annual Meeting of the American Society of Hematology. Mylotarg was originally approved in 2000 under […]

View full entry

Tags: Acute Myeloid Leukemia, Leukemia, News


November 1st, 2013

Busulfex Superior to Total Body Irradiation in AML in First Remission

By

Myeloablative conditioning with cyclophosphamide and Busulfex® (intravenous busulfan) was associated with better leukemia-free and overall survival than conditioning with cyclosphosphamide and total-body irradiation (TBI) in patients with acute myeloid leukemia (AML) who were in first complete remission after receiving an allogeneic stem cell transplant, according to the results of a study published in Blood. Acute myeloid […]

View full entry

Tags: Acute Myeloid Leukemia, Leukemia, News


January 18th, 2013

CPX-351 Highly Active in Older Patients with AML

By

CPX-351 is highly active in all patient subgroups and produced the greatest benefits in response rate and reduction in 60-day mortality compared to standard therapy in older patients with secondary acute myeloid leukemia and adverse cytogenetics, according to the results of a phase IIB study presented at the 54th Annual Meeting of the American Society […]

View full entry

Tags: Acute Myeloid Leukemia, Leukemia, News


January 14th, 2013

Combination of Revlimid and Vidaza Beneficial in Untreated Elderly Patients with AML

By

The sequential combination of Vidaza® (azacitidine) and Revlimid® (lenalidomide) shows evidence of clinical activity as initial therapy for older patients with acute myeloid leukemia, according to the results of a phase II study presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia. Acute myeloid leukemia (AML) is a cancer […]

View full entry

Tags: Acute Myeloid Leukemia, Leukemia, News


December 19th, 2012

Quizartinib Shows Promise in Treatment-Resistant AML

By

The targeted agent quizartinib showed promise in the treatment of a subset of patients with treatment-resistant acute myeloid leukemia (AML), according to the results of a study presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia. Acute myeloid leukemia is a cancer of the bone marrow and blood characterized […]

View full entry

Tags: Acute Myeloid Leukemia, Leukemia, News


May 2nd, 2012

Low Doses of Mylotarg May Improve Survival in Older Patients with Acute Myeloid Leukemia

By

Patients age 50-70 with previously untreated acute myeloid leukemia (AML) who are treated with Mylotarg® (gemtuzumab ozogamicin) plus standard chemotherapy appear to live longer than those who are treated with standard chemotherapy alone, according to the results of a study published in The Lancet. Acute myeloid leukemia (AML) is a cancer of the bone marrow […]

View full entry

Tags: Acute Myeloid Leukemia, Leukemia, News